Aries Wealth Management T Scan Therapeutics, Inc. Put Options Transaction History
Aries Wealth Management
- $361 Million
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
Others Institutions Holding TCRX
# of Institutions
89Shares Held
39MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.36MShares$7.61 Million2.73% of portfolio
-
Bvf Inc San Francisco, CA4.89MShares$6.94 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$6.34 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.5MShares$4.97 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$3.95 Million0.05% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $26.9M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...